Your browser doesn't support javascript.
loading
A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants.
Kim, Sehee; Wang, Miao; Tyrer, Jonathan P; Jensen, Allan; Wiensch, Ashley; Liu, Gang; Lee, Alice W; Ness, Roberta B; Salvatore, Maxwell; Tworoger, Shelley S; Whittemore, Alice S; Anton-Culver, Hoda; Sieh, Weiva; Olson, Sara H; Berchuck, Andrew; Goode, Ellen L; Goodman, Marc T; Doherty, Jennifer Anne; Chenevix-Trench, Georgia; Rossing, Mary Anne; Webb, Penelope M; Giles, Graham G; Terry, Kathryn L; Ziogas, Argyrios; Fortner, Renée T; Menon, Usha; Gayther, Simon A; Wu, Anna H; Song, Honglin; Brooks-Wilson, Angela; Bandera, Elisa V; Cook, Linda S; Cramer, Daniel W; Milne, Roger L; Winham, Stacey J; Kjaer, Susanne K; Modugno, Francesmary; Thompson, Pamela J; Chang-Claude, Jenny; Harris, Holly R; Schildkraut, Joellen M; Le, Nhu D; Wentzensen, Nico; Trabert, Britton; Høgdall, Estrid; Huntsman, David; Pike, Malcolm C; Pharoah, Paul D P; Pearce, Celeste Leigh; Mukherjee, Bhramar.
Affiliation
  • Kim S; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
  • Wang M; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
  • Tyrer JP; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
  • Jensen A; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Wiensch A; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
  • Liu G; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Lee AW; Department of Public Health, California State University, Fullerton, Fullerton, CA, USA.
  • Ness RB; University of Texas School of Public Health, Houston, TX, USA.
  • Salvatore M; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
  • Tworoger SS; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
  • Whittemore AS; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Anton-Culver H; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Sieh W; Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Olson SH; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
  • Berchuck A; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Goode EL; Department of Genetics and Genomic Sciences, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Goodman MT; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Doherty JA; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
  • Chenevix-Trench G; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • Rossing MA; Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Webb PM; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Community and Population Health Research Institute, Los Angeles, CA, USA.
  • Giles GG; Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Terry KL; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Ziogas A; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Fortner RT; Department of Epidemiology, University of Washington, Seattle, WA, USA.
  • Menon U; Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Gayther SA; Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Wu AH; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Song H; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Brooks-Wilson A; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Bandera EV; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Cook LS; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Cramer DW; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Milne RL; Gynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
  • Winham SJ; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Kjaer SK; Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Modugno F; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Thompson PJ; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Chang-Claude J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
  • Harris HR; Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
  • Schildkraut JM; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
  • Le ND; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Wentzensen N; University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM, USA.
  • Trabert B; Division of Cancer Care, Department of Population Health Research, Alberta Health Services, Calgary, AB, Canada.
  • Høgdall E; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Huntsman D; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Pike MC; Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Pharoah PDP; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Pearce CL; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
  • Mukherjee B; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Int J Cancer ; 144(9): 2192-2205, 2019 05 01.
Article de En | MEDLINE | ID: mdl-30499236
ABSTRACT
As a follow-up to genome-wide association analysis of common variants associated with ovarian carcinoma (cancer), our study considers seven well-known ovarian cancer risk factors and their interactions with 28 genome-wide significant common genetic variants. The interaction analyses were based on data from 9971 ovarian cancer cases and 15,566 controls from 17 case-control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs. never) and rs13255292 (p value = 3.48 × 10-4 ). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI = 0.46-0.60) compared to 0.71 (95%CI = 0.66-0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1-5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene-environment analysis in ovarian cancer.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Prédisposition génétique à une maladie / Exposition environnementale / Interaction entre gènes et environnement Type d'étude: Etiology_studies / Observational_studies / Risk_factors_studies Limites: Female / Humans Langue: En Journal: Int J Cancer Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Prédisposition génétique à une maladie / Exposition environnementale / Interaction entre gènes et environnement Type d'étude: Etiology_studies / Observational_studies / Risk_factors_studies Limites: Female / Humans Langue: En Journal: Int J Cancer Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...